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Abstract Regulator of calcineurin 1 (RCAN1) is an
endogenous inhibitor of the calcineurin pathway in cells. It
is expressed as two isoforms in vertebrates: RCAN1.1 is
constitutively expressed in most tissues, whereas tran-
scription of RCAN1.4 is induced by several stimuli that
activate the calcineurin-NFAT pathway. RCAN1.4 is
highly upregulated in response to VEGF in human
endothelial cells in contrast to RCAN1.1 and is essential
for efficient endothelial cell migration and tubular mor-
phogenesis. Here, we show that RCAN1.4 has a role in the
regulation of agonist-stimulated VEGFR-2 internalisation
and establishment of endothelial cell polarity. siRNA-me-
diated gene silencing revealed that RCAN1 plays a vital
role in regulating VEGF-mediated cytoskeletal reorgani-
sation and directed cell migration and sprouting angio-
genesis. Adenoviral-mediated overexpression of RCAN1.4
resulted in increased endothelial cell migration. Antisense-
mediated morpholino silencing of the zebrafish RCAN1.4
orthologue revealed a disrupted vascular development
further confirming a role for the RCAN1.4 isoform in
regulating vascular endothelial cell physiology. Our data
suggest that RCAN1.4 plays a novel role in regulating
endothelial cell migration by establishing endothelial cell
polarity in response to VEGF.
Keywords VEGFR-2  RCAN1  Endothelial 
Polarisation  Migration  Angiogenesis
Introduction
Angiogenesis is the process via which new blood vessels
are formed from pre-existing vessels. Physiological
angiogenesis is critical for normal physiological develop-
ment [1], whilst pathological angiogenesis plays a role in
the development of inflammatory diseases, cancer and
diabetic retinopathy [2–4]. Vascular endothelial growth
factor A (VEGF) is a potent pro-angiogenic regulator
which is secreted by tissues in response to hypoxia or
inflammation [5].
VEGF signalling in vascular endothelial cells is pri-
marily mediated by VEGF receptor 2 (VEGFR-2) [6]. The
binding of VEGF to VEGFR-2 results in receptor activa-
tion, characterised by receptor autophosphorylation and
initiation of a series of signalling cascades within the cell
resulting in migration, cell survival and proliferation [6–8].
Phosphorylation of the tyrosine 1175 residue within the
intracellular C-terminal domain of the receptor induces
activation of phospholipase C-c (PLCc) [9], which
hydrolyses phosphatidylinositol (4,5)-bisphosphate (PIP2),
to generate inositol (1,4,5)-trisphosphate (IP3) and
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diacylglycerol (DAG). IP3 acts upon receptors on the
endoplasmic reticulum (ER) to induce the release of
intracellular stores of Ca2?. This increase in Ca2? induces
activation of the protein phosphatase calcineurin (PP2B)
[10]. Dephosphorylation of nuclear factor of activated
T-cells (NFAT) by calcineurin results in its translocation to
the nucleus, where, in cooperation with other transcription
factors, it induces the transcription of a number of VEGF-
responsive genes important for regulating endothelial cell
physiology [11, 12].
Regulator of calcineurin 1 (RCAN1) belongs to a
family of endogenous negative regulators of calcineurin
action [13]. Originally named Down syndrome critical
region 1 (DSCR1), the human RCAN1 gene is located on
the 21q22.1-q22.2 region of chromosome 21 and is
expressed primarily in brain, heart and skeletal muscle
[14] and in endocrine tissues such as the adrenal gland
[15] and pancreas [16]. The RCAN1 gene is composed of
seven exons and alternative splicing generates two iso-
forms: RCAN1.1 (252 amino acids, 39 kDa) and
RCAN1.4, (192 amino acids; 29 kDa) which have iden-
tical C-terminal domains but differ at their N-termini due
to the actions of alternative promoters, leading to the
inclusion of either exon 1 or exon 4, respectively [14].
RCAN1.1 is constitutively expressed in most tissues,
whereas transcription of RCAN1.4 is induced by several
stimuli that activate the calcineurin-NFAT pathway
[17, 18]. The role of RCAN1 in vivo has been studied in
RCAN1-/- mice where gene ablation of RCAN1.1 and
RCAN1.4 resulted in mice with no anatomical differences
[19]. However, another study has shown that vascular
contraction is reduced in RCAN1-/- mice suggesting that
RCAN1 may regulate vascular function [20]. A more
recent study with RCAN1-/- mice focussing on tumour
angiogenesis reported hyperactivation of the calcineurin/
NFAT pathway in endothelial cells from these mice,
resulting in endothelial cell apoptosis. This led to
decreased tumour angiogenesis in a human tumour
xenograft study [21]. RCAN1.4 was identified as a
VEGF-responsive gene in endothelial cells [20, 22, 23]
and has been shown to negatively regulate VEGF-medi-
ated gene expression [14, 24] and regulate VEGF-medi-
ated endothelial cell migration [24, 25].
In this study, we were interested in determining the
mechanism through which RCAN1.4 regulates endothelial
cell migration. We have utilised siRNA-mediated silencing
of RCAN1 and adenoviral-mediated overexpression of
RCAN1.1 and RCAN1.4 splice variants to reveal that
RCAN1.4 is able to drive the directed migration of
endothelial cells via a transient interaction with VEGFR-2.
The ability of RCAN1.4 to regulate vascular formation
in vivo was identified in zebrafish embryos.
Materials and methods
Materials
Human recombinant VEGF-A165 and HGF were obtained
from Peprotech. Fibroblast growth factor-2 (FGF-2) was
obtained from R&D Systems. All other materials were
obtained from Invitrogen unless otherwise stated.
Antibodies
Antibodies against phospho-VEGFR-2 (Y1173, #3770),
phospho-AKT (S473, #4058), phospho-ERK1/2 (T202/
Y204, #9101), VEGFR-2 (#2479), phospho-HGFR/c-Met
(Y1349; #3121) transferrin receptor (TfR) (#13113) and
GAPDH (#5174) were purchased from Cell Signalling
Technology (New England Biolabs). The antibody against
RCAN1 (#D6694) was purchased from Sigma. Antibody
against GM130 (#610823) was purchased from BD Bio-
science. The antibody against pericentrin (#ab4448) was
purchased from Abcam. Antibodies against VEGFR-2 (N-
terminal extracellular domain; #AF357), HGFR/c-Met (N-
terminal extracellular domain; #AF276) and calcineurin-A
(#MAB2839) were purchased from R&D Systems.
Cell culture
HDMEC (#C-12210; juvenile) were purchased from Pro-
mocell and were cultured in endothelial cell basal media
(EBM) MV2 growth media (C-22221; Promocell), sup-
plemented with 5% (v/v) foetal calf serum (FCS) and EGF
(5 ng/ml), VEGF-A (0.5 ng/ml), FGF-2 (10 ng/ml), long r3
insulin growth factor-1 (20 ng/ml), hydrocortisone (0.2 lg/
ml) and ascorbic acid (1 lg/ml) (supplement pack
C-39221; Promocell). Cells were routinely cultured on
0.5% (w/v) gelatin-coated plates in a humidified incubator
under 5% CO2 at 37 C. HEK 293 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% (v/v) FCS. For growth factor stimulation,
cells were serum starved for at least 16 h by changing
media to media supplemented with 1% (v/v) FCS without
growth factor supplements. Growth factors were used for
the times indicated at 50 ng/ml.
siRNA transfection
The following siRNA duplexes were obtained from Qia-
gen: RCAN1 (Hs_DSCR1_5 HP, SI03224900;
Hs_DSCR1_6 HP, SI03246208) and VEGFR-2
(Hs_KDR_5, SI00605528; Hs_KDR_6, SI00605535).
siRNA duplexes were used at a final total concentration of
10 nM in 0.1% (v/v) Lipofectamine RNAiMAX, according
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to the manufacturer’s instructions. Control non-silencing
(N.S.) transfections were performed using all-stars Nega-
tive Control siRNA (Qiagen) at a concentration of 10 nM.
Transfection reactions were performed in serum-free
OptiMEM (Life Technologies). Cell media were changed
to serum containing media 6 h after transfection and cells
were left for a further 48 h prior to experiments.
Adenoviral overexpression
HDMECs were plated at 50,000 cells/well in 12 well
plates. Cells were grown for 24 h in the plates and infected
with an empty control virus (Ad-Control) or adenovirus
encoding human RCAN1.1 (Ad-RCAN1.1) and RCAN1.4
(Ad-RCAN1.4) [26] at a multiplicity of infection (MOI) of
50. After 6 h, the virus was removed and the media were
changed to 1% (v/v) FCS EBM for 20 h before stimulation
with growth factors.
Western immunoblotting
Cells were harvested in ice-cold lysis buffer (20 mM Tris
pH7.5, 150 mM NaCl, 2.5 mM EDTA, 10% (w/v) glycerol
and 1% (w/v) Triton X-100, 1 mM Na3VO4 (Sigma #S-
6508), 10 lg/ml Aprotinin (Sigma #A-4529), 10 lg/ml
Leupeptin (Sigma #L-8511), 10 lg/ml Pepstatin, 1 mM
PMSF) and kept on ice with gentle agitation for 15 min to
allow complete lysis. The cells were scraped into 1.5 ml
Eppendorf tubes and cleared of cell debris by centrifuga-
tion at 17,000 9g for 20 min at 4 C and the supernatant
transferred to fresh tubes. Total solubilised protein was
measured using the BCA method (Pierce). For SDS-PAGE
an appropriate volume of 1 9 LDS (Life Technology
#NP0008) sample loading buffer was added to the sample
(10 lg of protein), which was then heated at 90 C for
5 min before loading onto pre-cast 4-12% Bis–Tris
NuPAGE gels (Thermo Fisher Scientific). Proteins were
separated using MOPS SDS running buffer (Thermo Fisher
Scientific) for 2 h at 200 V and 50 mA. Proteins were
transferred to nitrocellulose (Hybond C, GE Healthcare)
and membranes blocked in 5% (w/v) BSA. Blots were
probed with primary antibody in 2% (w/v) BSA followed
by secondary HRP-coupled antibody, after several washes.
Washed membranes were incubated in enhanced chemilu-
minescence substrate (RPN2106; GE Healthcare) and
developed using Fuji Medical X-Ray Film, Super RX,
100NF (Jet X-Ray, UK). The immune reactive bands
detected on X-ray film were quantified by scanning (Bio
Rad #GS-800, Photoshop CS6) and densitometric analysis
achieved using ImageJ (National Institute of Health (NIH),
Version 1.47n). GAPDH levels were quantified to correct
for protein loading.
Immunoprecipitation
Cells were seeded on gelatin-coated dishes in normal
growth media for 24 h. Adenovirus was added to cells for
6 h. Media were changed to 1% (v/v) FCS-containing
media for 20 h before stimulation with VEGF (50 ng/ml)
for 0, 2, 10 and 30 min. Cells were harvested in ice-cold
lysis buffer (20 mM Tris pH7.5, 150 mM NaCl, 2.5 mM
EDTA, 10% (w/v) glycerol and 1% (w/v) Triton X-100,
1 mM Na3VO4 (Sigma #S-6508), 10 lg/ml Aprotinin
(Sigma #A-4529), 10 lg/ml Leupeptin (Sigma #L-8511),
10 lg/ml Pepstatin, 1 mM PMSF) and kept on ice with
gentle agitation for 15 min to allow complete lysis. The
cells were scraped into 1.5 ml Eppendorf tubes and cleared
of cell debris by centrifugation at 17,000 9g for 20 min at
4 C and the supernatant transferred to fresh tubes. Lysates
were incubated with anti-RCAN1 antibody (25 lg/mL) or
control rabbit IgG (25 lg/mL, Millipore #12-370) rotating
end over end for 20 h at 4 C. Protein G Sepharose was
added to this for a further 3 h before samples were cen-
trifuged at 10,000 9 g for 1 min and washed three times
with lysis buffer. Supernatant was removed and the sam-
ples resuspended in LDS sample buffer before boiling at
90 C for 5 min. Lysates were resolved by SDS-PAGE gels
followed by the western blotting protocol. For IP experi-
ments, Goat anti-Rabbit IgG-HRP Fc-specific (#111-035-
046, Jackson Labs) was used for detecting RCAN1 Ab.
Cell surface biotinylation and internalisation
HDMECs were plated in 6 cm dishes in normal growth
media for 48 h. Media were then changed to 1% (v/v) FCS-
containing media for 24 h. Cell monolayers were washed
in PBS containing Mg2? and Ca2? and incubated with
sulfo-NHS-SS-biotin (0.5 mg/ml) (Thermo Fisher Scien-
tific) for 30 min at 4 C. Following surface labelling, cells
were washed in PBS and incubated with endothelial media
containing 1% FCS v/v. Cells were stimulated with VEGF
(50 ng/ml) for 10 min. Following stimulation and receptor
internalisation, cells were then transferred onto ice and
washed twice with ice-cold PBS and biotin removed from
proteins remaining at the cell surface by reduction with
100 mM 2-mercaptoethanesulphonate (MesNa; Sigma) in
50 mM Tris, 100 mM NaCl (pH 8.6) for 2 9 10 min at
4 C. To evaluate efficiency of biotin cleavage, control
cells were kept in PBS without MesNa during this step.
Unreacted MesNa was quenched with 20 mM iodoac-
etamide (Sigma) for 10 min and the cells lysed in ice-cold
lysis buffer as above. Pre-cleared lysates were incubated
with streptavidin coupled agarose at 4 C and mixed by
end-over-end rotation at 4 C for 3 h. Beads were cen-
trifuged at 17,000 9 g for 1 min and washed 9 3 in lysis
buffer and resuspended in 50 ll of 2 9 LDS sample buffer.
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Samples were analysed by SDS-PAGE before
immunoblotting for VEGFR-2 and TfR.
Immunofluorescence imaging
Cells were plated on gelatin-coated glass coverslips. Fol-
lowing agonist stimulation, coverslips were washed twice
in PBS and fixed with 2% (w/v) PFA for 15 min at room
temperature. Cells were quenched in PBS containing
50 mM ammonium chloride and then permeabilised in
PBS containing 0.2% (w/v) Triton X-100 for 10 min at
room temperature. Cells were washed in PBS and then
blocked for 1 h at room temperature with TBS containing
0.1% (v/v) Tween-20 and 5% (w/v) BSA. Coverslips were
incubated with primary antibody in TBS containing 0.1%
(v/v) Tween-20 and 1% (w/v) BSA. Cells were
washed 9 5 in TBST and then incubated with the relevant
secondary Alexa Fluor coupled antibodies for 1 h at room
temperature. Samples were then incubated for 10 min with
Hoechst 33342 (Invitrogen #H-21492) and mounted with
Prolong gold (Invitrogen). Fluorescent images were
acquired with a Zeiss AxioObserver inverted fluorescence
microscope with Apotome2 using a Plan-Apochromat 40x/
1.3 oil immersion objective and Zeiss ZenPro software.
Scratch wound migration assay
HDMECs were seeded in a 12-well plate in normal growth
media for 48 h. Media were then changed to 1% (v/v) FCS-
containing media for 24 h and a scratch introduced into the
cell monolayer using a sterile 200 ll pipette tip. Cells were
stimulated with growth factor for 18 h before washing with
PBS then fixed with 2% (w/v) PFA for 15 min at room
temperature. The scratch was visualised using a Nikon
Eclipse TS100 inverted light microscope (109 objective)
fitted with LCD colour imaging system. To calculate cell
migration, a time zero image was taken immediately after
scratch wounding the cells. After 18 h, a further three
images were taken of each scratch and migration measured
in each image to give an average value for each condition
compared to the time zero point.
Time-lapse chemotaxis assays
HDMECs were seeded in a 12-well plate in normal growth
media for 48 h. Media were then changed to 1% (v/v) FCS-
containing media for 24 h and a scratch introduced into the
cell monolayer using a sterile 200 ll pipette tip. Cells were
stimulated with growth factor, and migration of individual
cells was recorded at 5 min intervals with an Axiovert
200 M inverted microscope with atmosphere control unit
for 18 h using a 209 objective and digital video recording.
Migration trajectories were tracked for 20 individual cells
over 20 h using Ibidi chemotaxis and migration tool.
Cell polarisation
Confluent monolayers of HDMECs were grown on gelatin-
coated coverslips and serum starved for 20 h. A horizontal
wound was created in the confluent monolayer using a
sterile 200 ll pipette tip and cells stimulated with VEGF
(50 ng/ml) for 18 h. Subsequently, cells were fixed in
2% (w/v) PFA in PBS for 10 min and permeabilised in
0.25% (w/v) Triton X-100 in PBS for 5 min followed by 1
h blocking in 2% (w/v) BSA in PBS at room temperature.
After blocking, cells were incubated for 1 h in primary
antibody staining Golgi (GM130; 1:100 in 2% (w/v) BSA
in PBS) and centrosomes (Pericentrin; 1:100 in 2% (w/v)
BSA in PBS). Cells were subjected to an additional incu-
bation of 1 h with a mixture of a fluorescently labelled
Alexa Fluor secondary antibody and Hoechst 33342 at
room temperature. Cells were washed at least three times
between each step. Following mounting, images were
captured using an inverted Zeiss AxioObserver inverted
fluorescence microscope with Plan-Apochromat 20x/0.8
and Zeiss ZenPro software. The polarity index was deter-
mined as previously described [27]. Briefly, cells in which
the Golgi and centrosome was located within the 120 C
angle facing the major axis of the wound were scored as
polarised. A total of 100 cells from each of three inde-
pendent experiments were analysed to determine the
polarity index.
Proximity ligation assay (PLA)
HDMECs were seeded on gelatin-coated glass coverslips in
normal growth media for 48 h. Media were then changed to
1% (v/v) FCS-containing media for 24 h and a scratch
introduced into the cell monolayer using a sterile 200 ll
pipette tip. Cells were allowed to recover for 1 h prior to
agonist stimulation for the required time. Cells were fixed
in 4% (w/v) PFA on ice for 10 min and permeabilised in
PBS containing 0.1% (v/v) Triton X-100 for 20 min and
thereafter subjected to in situ PLA using the Duolink
Detection kit (Olink Bioscience, Uppsala, Sweden)
according to the manufacturer’s instructions for Duolink
Blocking solution and Detection protocol. Briefly, slides
were blocked, incubated with antibodies directed against
VEGFR-2 (R&D, Goat anti-human VEGFR-2 #AF357)
and RCAN1 (Sigma, Rabbit anti-RCAN1, #D6694) and
thereafter incubated with relevant PLA probes conjugated
to unique oligonucleotides. Circularisation and ligation of
the oligonucleotides were followed by an amplification
step. The products were detected by a complementary
fluorescently labelled probe, and slides were mounted
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using Vectashield (Vector Laboratories Inc, Burlingame,
CA) and evaluated using a Zeiss AxioObserver inverted
fluorescence microscope. Z-stack micrographs were taken
with the Plan-Apochromat 40x/1.3 oil immersion objective
and Zeiss ZenPro software. The number of proximity
ligations, visualised as bright fluorescent signals, was
counted in 20 fields/well for cells at the leading edge and
also for cells not at the edge in the main body. Quantifi-
cations are given as mean ± s.e.m.
3D in vitro sprouting angiogenesis assay
A sprouting angiogenesis assay was performed as described
[28]. HDMEC were grown on gelatin-coated dishes. Four
hours after siRNA transfection, cells were labelled with either
5 lM cell tracker green CMFDA (Invitrogen #C2925) or
5 lM cell tracker orange CMRA (Invitrogen #C34551) for
45 min. Labelled HDMECs were detached by accutase and
mixed equally 1:1 to give a final cell number of 1000 and
incubated with 0.20% (w/v) carboxymethylcellulose and see-
ded in ultra-low adherent (ULA) round-bottom 96-well plates
(Corning) and grown overnight. 16-24 h later, spheroids were
collected and embedded into 200 ll of collagen I gel in glass
bottom dishes (Greiner). After polymerisation, spheroids were
cultured for 24 h in the presence of EBM2medium containing
1% (v/v) FCS and VEGF (50 ng/ml). Cells were fixed in 2%
(w/v) PFA for 10 min and sprouting angiogenesis analysed by
immunofluorescence using a Plan-Apochromat 20x/0.8 and
Zeiss ZenPro software. The number of tip and stalk cells of
each colour were counted. Experiments were repeated
reversing the cell tracker dyes to ensure no dye bias.
Zebrafish analysis
The transgenic lineofzebrafishTG(fli1:GFP) [29]werebred to
produce embryos. Embryos were microinjected at the 1–2 cell
stage with 5 ng of either mismatch or morpholino oligonu-
cleotide solutions (MOs) [30]. Co-injection of phenol red was
performed to act as a tracer for the injection procedure. The
morpholino sequences were RCAN1a-4: ACTT-
CATTGTTTTCAGGTGCATGAC and mismatch control:
ACaTgATTcTTTTgAGcTGCATGAC (Gene Tools, Oregon,
USA). Vasculature imaging at 48 hpf was performed using a
Zeiss 780 Zen confocal microscope. Computer analysis of the
vasculature was performed using ImageJ and the following
plugins: Skeletonise (2D/3D) and Analyze Skeleton plugins.
Statistical analysis
Statistical analysis was performed using an unpaired Stu-
dent’s t test in Excel. P values\0.05 were considered
significant. *P\ 0.05, **P\ 0.01, ***P\ 0.001.
Results
RCAN1 regulates VEGFR-2 internalisation
following ligand stimulation
Human RCAN1 comprises seven exons, which are alter-
natively spliced resulting in two major protein isoforms
RCAN1.1 (252 amino acids) and RCAN1.4 (197 amino
acids). The proximal promoter regulating expression of
RCAN1.4 is activated by calcineurin-NFAT signalling in
response to different stimuli such as VEGF [22, 23]. We
have previously shown that in endothelial cells, VEGF
stimulates an increase in RCAN1.4 expression but not
RCAN1.1 [24]. We subsequently showed that RCAN1 was
required for VEGF/VEGFR-2 mediated migration of
endothelial cells. In the current study, we were interested in
determining the mechanism by which RCAN1 regulates
VEGFR-2 function and endothelial cell migration.
Ligand binding to VEGFR-2 results in activation of an
intracellular signalling cascade and ubiquitination and
receptor internalisation followed by proteolytic degradation
[31]. In HDMECs, VEGF stimulation led to a transient
increase in VEGFR-2 phosphorylation and time-dependent
decrease in total VEGFR-2 levels (Fig. 1a, b). To analyse
downstream signalling pathways, we measured AKT phos-
phorylation, which is required for endothelial cell survival
and ERK1/2 phosphorylation, required for cell proliferation
[6]. VEGF stimulation resulted in a transient increase in
AKT phosphorylation and ERK1/2 phosphorylation. VEGF
stimulation also resulted in an increase in RCAN1.4
expression after 30–60 min with no apparent increase in
RCAN1.1 levels (Fig. 1a, b). In order to analyse the role of
RCAN1 in VEGFR-2 phosphorylation and downstream
signalling, we utilised short-interfering RNA (siRNA)-me-
diated gene silencing. The duplexes utilised target both
isoforms of RCAN1 (RCAN1.1 and RCAN1.4) as it was not
possible to design isoform specific duplexes. siRNA-medi-
ated silencing of RCAN1 resulted in a delayed VEGFR-2
downregulation following VEGF stimulation with a con-
comitant increase in receptor phosphorylation (Fig. 1a, b).
In order to analyse cell surface VEGFR-2 levels, we
utilised an antibody to the external N-terminal domain of
VEGFR-2 and performed immunofluorescence analysis
following ligand stimulation in the absence of permeabil-
isation. Stimulation with VEGF resulted in a time-depen-
dent decrease in surface VEGFR-2 levels in HDMECs, an
effect substantially reduced following siRNA-mediated
silencing of RCAN1 (Fig. 2a). To confirm this effect on
cell surface VEGFR-2, we utilised cell surface labelling
with cleavable biotin. Following stimulation with VEGF,
VEGFR-2 that has undergone internalisation from the
membrane is protected from biotin cleavage and can be
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specifically analysed in cell lysates by immunoprecipita-
tion with streptavidin-agarose. This method confirmed that
VEGF stimulation resulted in VEGFR-2 internalisation at
10 min, an effect that was substantially reduced by
silencing of RCAN1 (Fig. 2b, c). Analysis of the inter-
nalisation of the transferrin receptor (TfR), which under-
goes constitutive internalisation and recycling in cells
[32, 33], revealed that silencing of RCAN1 did not affect
internalisation of the TfR (Fig. 2b).
In order to see if this effect of RCAN1 silencing on
receptor levels and downstream signalling was apparent
with another RTK expressed on HDMECs, we analysed the
levels of the hepatocyte growth factor receptor (HGFR/c-
Met) following stimulation with HGF. Analysis of HGFR
by western blotting revealed that RCAN1 silencing did not
appear to affect HGFR levels (Supplementary Fig. 1a, b).
Further analysis by immunofluorescence using an antibody
to the extracellular N-terminal domain of HGFR in the
absence of cell permeabilisation revealed no apparent
effect of RCAN1 silencing on HGF-stimulated HGFR
internalisation (Supplementary Fig. 2).
RCAN1 regulates VEGFR-2-mediated endothelial
cell polarity and cytoskeletal reorganisation
Directed cell migration in response to agonists requires
asymmetric activation of cell membrane receptors to
induce polarised signals that result in the generation of
protrusions at the front of the cell (leading edge) and
retraction at the back of the cell (trailing edge) [34, 35].
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Fig. 1 RCAN1 regulates VEGFR-2 levels in HDMECs. a Endothelial
cells were left untransfected or transfected with non-silencing siRNA
(N.S. siRNA) or RCAN1 siRNA. Cells were left unstimulated or
stimulated with VEGF165 (50 ng/ml) for a range of time (5, 10, 30,
60, 180 min). Cells were lysed and immunoblotted with antibodies to
VEGFR-1, phospho-VEGFR-2 (Y1175), VEGFR-1, phospho-AKT
(S473), phospho-ERK1/2 (T202/Y204), GAPDH and RCAN1.
Results are from one experiment representative of three separate
experiments. b Quantification of levels of VEGFR-2, phospho-
VEGFR-2, and RCAN1.1 and RCAN1.4. Levels are calculated
relative to % of basal untransfected (mean ± s.e.m. n = 3 indepen-
dent experiments). *P\ 0.05, ** P\ 0.01, ***P\ 0.001 (unpaired
student’s t test comparing RCAN1 siRNA and N.S. siRNA)
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Analysis of the cytoskeletal reorganisation at the scratch
wound edge in HDMECs revealed that VEGF induced a
number of cellular protrusions reminiscent of filopodia
(Fig. 3a). This effect was blocked by siRNA-mediated
silencing of RCAN1 expression as leading edge cells were
devoid of any protrusions under both basal and VEGF-
stimulated conditions. However, HGF, which does not
induce RCAN1.4 levels (Supplementary Fig. 1a), was able
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Fig. 2 RCAN1 regulates VEGFR-2 internalisation. a HDMECs were
left untransfected or transfected with either non-silencing siRNA
(N.S. siRNA) or RCAN1 siRNA. Cells were stimulated with VEGF
(50 ng/ml) for 10, 30 and 60 min. Cells were fixed in 2% PFA and
left unpermeabilised. Cells were incubated with goat anti-VEGFR-2
antibody (recognising the N-terminal, extracellular domain) followed
by incubation with donkey anti-goat Alexa488 antibody. Nuclei were
stained with Hoechst 33342. Scale bar represents 20 lm. b HDMECs
were left untransfected or transfected with non-silencing siRNA
(N.S.siRNA) or RCAN1 siRNA. Cells were surface labelled with
cleavable biotin and stimulated or not with VEGF (50 ng/ml) for
10 min. Biotin remaining on the surface was cleaved with MesNa and
biotinylated proteins immunoprecipitated with streptavidin-agarose.
Internalised VEGFR-2 and transferrin receptor (TfR) were detected
by Western blotting. Efficiency of biotin cleavage was analysed in
untransfected cells without MesNa. The level of VEGFR-2, TfR and
GAPDH was analysed in total cell lysate. c Quantification of
internalised VEGFR-2 (mean ± S.D. from three individual experi-
ments). *P\ 0.05, **P\ 0.01, (unpaired student’s t test)
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Fig. 3 RCAN1 regulates VEGF-mediated cytoskeletal reorganisation
and cell polarity. a HDMECs were grown on gelatin-coated glass
coverslips. Cells were left untransfected or transfected with either
non-silencing siRNA (N.S. siRNA) or RCAN1 siRNA. A horizontal
wound was introduced on the glass coverslip. Cells were stimulated or
not with either VEGF (50 ng/ml) or HGF (50 ng/ml) for 3 h. Cells
were fixed in 2% PFA, permeabilised and stained for RCAN1.
Cytoskeletal reorganisation was visualised by staining F-actin with
phalloidin-Alexa Fluor 588. Nuclei were stained with Hoechst 33342.
Scale bar represents 20 lm. b HDMECs were grown on gelatin-
coated glass coverslips. Cells were left untransfected or transfected
with either control non-silencing siRNA (N.S. siRNA) or RCAN1
siRNA. A horizontal wound was introduced on the glass coverslip.
Cells were stimulated or not VEGF (50 ng/ml) for 3, 6 and 12 h. Cells
were fixed in 2% PFA, permeabilised and stained for golgi (GM130)
and centrosomes (pericentrin). Cell polarisation towards the wound
was assessed by drawing a circle centred over the nucleus with a 120
segment facing the wound. Cells were polarised if the golgi and
centrosome were located within this 120 segment. Scale bar
represents 20 lm. c Quantification of cell polarisation. The percent-
age of polarised cells was calculated by counting 100 cells per
treatment. Results are plotted as % of cells polarised at the leading
edge (mean ± s.e.m. n = 3 independent experiments). *P\ 0.05,
**P\ 0.01, ***P\ 0.001
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to induce cytoskeletal reorganisation even in HDMECs
with depleted RCAN1 levels, revealing that RCAN1 did
not block cytoskeletal reorganisation per se (Fig. 3a). The
scratch wound assay allows analysis of cell polarity, as
directed migration in this assay is accompanied by reor-
ganisation of the centrosome and Golgi apparatus, relative
to the nucleus, to face the direction of cell migration
[36, 37]. To analyse the effect of RCAN1 silencing on
HDMEC cell polarity, we visualised the orientation of the
Golgi using an antibody to GM130 and the centrosome
using an antibody to pericentrin. Following VEGF stimu-
lation of HDMECs cell polarity increased at the leading
edge over a period of 6 h from 28 ± 2 to 70 ± 5%. This
increase in cell polarity was considerably reduced in
RCAN1-depleted cells, achieving a maximum of only
50 ± 5% (Fig. 3b).
RCAN1.4 regulates VEGFR-2 dependent
endothelial cell migration
Our previous studies have identified a role for RCAN1.4 in
regulating VEGF-mediated migration of endothelial cells
using a scratch wound assay [24]. We were interested in
determining the specificity of RCAN1.4 in regulating
VEGF function. RCAN1 silencing specifically inhibited
cell migration in response to VEGF, but not HGF (Fig. 4a).
The finding that RCAN1 depletion causes a defect in cell
migration led us to examine the directionality of migration.
We utilised time-lapse DIC imaging of HDMEC following
scratch wounding and agonist stimulation with VEGF or
HGF. Migration trajectories were tracked for 20 individual
cells over 20 h using the Ibidi chemotaxis and migration
tool. RCAN1 depletion resulted in a slower and more
convoluted migration in response to VEGF compared to
untransfected and non-silencing conditions (Fig. 4b). In
contrast, RCAN1 depletion did not affect HGF-stimulated
cells, which showed normal distance and trajectory indi-
cating that RCAN1 silencing did not block migration per
se. Similarly, the velocity (total path length/time),
straightness (displacement/total path length) and forward
migration index [38] were significantly decreased for the
RCAN1-depleted cells stimulated with VEGF in contrast to
HGF (Fig. 4c). We have previously shown that RCAN1.4
levels are sustained for at least 9 h in HDMECs following
VEGF stimulation, with no change in RCAN1.1 levels
[24]. To confirm that RCAN1.4 was able to regulate
VEGFR-2-mediated migration in endothelial cells, we
utilised adenovirus-mediated gene transduction to specifi-
cally over-express the RCAN1.1 and RCAN1.4 isoforms in
HDMECs (Fig. 5a); levels of overexpression of RCAN1.4
were similar to levels induced by VEGF stimulation in
untreated cells. Infection with adenovirus encoding
RCAN1.4 resulted in an increase in HDMEC migration
similar to that evoked by VEGF (Fig. 5b, c). In contrast,
infection with adenovirus encoding RCAN1.1 did not
stimulate migration and inhibited VEGF-mediated migra-
tion, with no apparent effect on HGF-stimulated migration
(Fig. 5b, c).
We were interested in determining if the effect of over-
expression of RCAN1.4 on HDMEC migration was
dependent on VEGFR-2. To address this, we utilised
siRNA-mediated gene silencing to significantly reduce
VEGFR-2 expression in HDMECs (Fig. 6a). Cell migra-
tion stimulated by RCAN1.4 overexpression was prevented
in the cells treated with VEGFR-2 siRNA suggesting that
RCAN1.4-mediated cell migration required VEGFR-2
(Fig. 6b, c).
RCAN1.4 transiently co-localises and binds
with VEGFR-2
The profound effect of RCAN1 depletion on delaying
internalisation of ligand-activated VEGFR-2 suggested that
RCAN1 may interact directly with VEGFR-2. We utilised
a proximity ligation assay (PLA) to analyse any potential
spatial and temporal interaction between VEGFR-2 and
RCAN1. This technique generates a fluorescence signal at
the precise site of interaction of the proximity ligation
probes and consequently the primary antibodies targeting
RCAN1 and VEGFR-2 [39]. The PLA revealed a rapid and
transient increased co-localisation between VEGFR-2 and
RCAN1 in the HDMECs at the leading edge following
stimulation with VEGF (Fig. 7a, b). In order to explore the
potential association between RCAN1 and VEGFR-2 fur-
ther we overexpressed both the RCAN1.1 and RCAN1.4
variants in HDMECs using adenoviral-mediated gene
transduction. Immunoprecipitation of RCAN1 revealed
that only the RCAN1.4 variant was capable of transiently
interacting with VEGFR-2 (Fig. 8a). However, both
RCAN1 variants were capable of interacting with cal-
cineurin, a known binding partner of RCAN1 proteins [40].
Analysis of total cell lysate (TCL) revealed that overex-
pression of RCAN1.4 resulted in a transient increase in
VEGF-mediated downregulation of VEGFR-2 levels
compared with cells expressing Ad-RCAN1.1 and Ad-
Control (Fig. 8a, b).
RCAN1.4 regulates sprouting angiogenesis
and vascular development in zebrafish embryos
Sprouting angiogenesis requires endothelial tip cells to
become polarised and extend filopodia with the coordi-
nated regulation of stalk cells, allowing the formation and
stabilisation of the sprout and ultimately a lumen-con-
taining vessel [41]. We have previously shown that
RCAN1 is required for efficient tubular morphogenesis
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Fig. 4 RCAN1 regulates VEGF-mediated directional cell migration.
HDMECs were plated in gelatin-coated 24-well plates and transfected
with either non-silencing siRNA (N.S. siRNA) or RCAN1 siRNA
prior to incubation in media containing 1% FCS for 24 h. A
horizontal scratch wound was introduced. Cell were stimulated or not
with either VEGF165 (50 ng/ml) or HGF (50 ng/ml). Low-magnifi-
cation (49 objective) phase contrast time-lapse series were obtained
(images collected every 15 min for 18 h). a Images of cells following
18 h stimulation. b Migration trajectories of representative cells
(n = 20). Tracks of cells migrating in a representative field of
imaging. c Comparison of velocity (displacement/time), straightness
(displacement/total path length) and forward migration index (FMI)
(mean ± S.D., n = 3). *P\ 0.05, ***P\ 0.001 (unpaired student’s
t test)
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using a collagen gel assay [24]. To investigate the role of
RCAN1 in vascular sprouting we generated 3D endothelial
cell spheroids composed of a 1:1 mixture of non-silencing
control and RCAN1 siRNA silenced HDMECs labelled
with different fluorescent dyes and embedded these in a
collagen gel. RCAN1 depleted HDMECs showed a
reduced ability to achieve a tip position compared to
control cells when stimulated with VEGF (Fig. 9a, b).
The role of RCAN1.4 in angiogenesis in vivo was
investigated in zebrafish, using the transgenic Fli1-GFP
fish in which endothelial cells constitutively express GFP
[29]. Translation of the zebrafish RCAN1.4 orthologue
(RCAN1a-4) was blocked by micro-injection of an anti-
sense morpholino targeting the translational start site of
this splice variant; as a control a mismatch morpholino was
used. The fish embryos were imaged at 48 h post-fertili-
sation and the images analysed to determine total vessel
length and junction number. Knockdown resulted in a
disrupted vascular network with incomplete sprouting of
the intersomitic vessels and defective fusion at the dorsal
lateral anastomosing vessel (Fig. 9c). Analyses of the
images determined that there was a significant decrease in
the total vessel length and junction number in the mor-
pholino knockdown embryos (Fig. 9d). These data indicate
that RCAN1.4 plays a role in vascular development in
zebrafish.
Discussion
We have previously reported the novel finding that in
addition to its role in inhibiting calcineurin function and
subsequently VEGF-stimulated gene expression, RCAN1.4
is able to regulate VEGF-mediated tubular morphogenesis
in endothelial cells [24]. Our present study was designed to
determine the mechanism through which RCAN1.4 is able
to regulate VEGFR-2 signalling and affect endothelial cell
function. We now report the novel finding that RCAN1.4 is
able to specifically regulate VEGFR-2 internalisation and
subsequently cell polarisation leading to efficient directed
cell migration and vascular sprout formation.
Our previous work has shown that VEGF is unique,
compared with other growth factors such as FGF and
HGF, in stimulating RCAN1.4 expression in HDMECs
via a pathway requiring calcineurin and PKC-delta [24].
VEGF-mediated upregulation of RCAN1.4 has been pre-
viously thought to act as a negative feedback loop in
preventing calcineurin-mediated gene expression in
endothelial cells and tempering sustained VEGFR-2
activity. Use of siRNA targeting both the RCAN1.1 and
RCAN1.4 isoforms defined a role for RCAN1 in regu-
lating VEGFR-2 internalisation (Fig. 1, 2a), VEGF-me-
diated cytoskeletal reorganisation (Fig. 3a), cell
polarisation (Fig. 3b) and cell migration (Fig. 4). Our data
are in agreement with a previous study using antisense
oligonucleotides to RCAN1 which reported an inhibition
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Fig. 5 RCAN1.4 isoform stimulates endothelial cell migration.
HDMECs were plated on gelatin-coated 24-well plates and incubated
with adenovirus (Ad-Control) or adenovirus encoding RCAN1.1
isoform (Ad-RCAN1.1) or RCAN1.4 isoform (Ad-RCAN1.4) for
24 h. a Cells were lysed and western blotted for levels of RCAN1.1
(39 kDa) and RCAN1.4 (29 kDa) and GAPDH. VEGF stimulation
(50 ng/ml for 1 h) of untransfected cells were analysed for levels of
RCAN1.4 as a control. b Cells were incubated in media containing
1% FCS for 24 h and a horizontal scratch wound was introduced.
Cells were incubated with media (Basal) or stimulated with either
VEGF (50 ng/ml) or HGF (50 ng/ml) for 18 h. Cells were fixed in 2%
PFA. c Quantification of cell migration. Results are plotted as cell
migration, % of basal untreated response (mean ± S.D., n = 3).
***P\ 0.001 (unpaired student’s t test)
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of VEGF-mediated migration in human umbilical vein
endothelial cells (HUVECs) [25].
Overexpression of each RCAN1 isoform by use of
adenoviral-mediated gene transduction revealed that whilst
RCAN1.4 could stimulate endothelial cell migration, in the
absence of VEGF, RCAN1.1 did not stimulate migration
but instead inhibited VEGF-induced migration with no
effect on HGF-stimulated migration (Fig. 5b, c). This is in
agreement with a previous report showing that lentiviral-
mediated overexpression of RCAN1.1 inhibited VEGF-
mediated migration of HUVECs [42]. Taken together, this
data suggest that RCAN1 isoforms have contrasting func-
tions in regulating VEGF-mediated migration in endothe-
lial cells.
The ability of RCAN1.4 to regulate VEGF-mediated
migration required the presence of VEGFR-2 (Fig. 6a–c)
suggesting a potential interaction between RCAN1.4 and
VEGFR-2. RTK internalisation follows the canonical cla-
thrin-dependent endocytic route involving the small GTP
binding protein Rab5 [43, 44]. Analysis of the intracellular
interaction with VEGFR-2 and RCAN1 by proximity
ligation assay (PLA) showed a close association between
VEGFR-2 and RCAN1, which transiently increased at the
leading edge following VEGF stimulation (Fig. 7).
Immunoprecipitation revealed that whilst both RCAN1.1
and RCAN1.4 can interact with calcineurin, in agreement
with previous findings [40], only RCAN1.4 was able to
transiently bind to VEGFR-2 (Fig. 8a). Both RCAN1
proteins are able to inhibit calcineurin activity by binding
via their common c-terminal tail to the catalytic site on
calcineurin [40]. Taken together, this would suggest that
the unique N-terminal region of RCAN1.4 (Exon 4) tran-
siently interacts with VEGFR-2 at the leading edge of cells.
The lack of effect of siRNA-mediated silencing of RCAN1
expression on TfR internalisation (Fig. 2b) and agonist-
stimulated HGFR/c-Met internalisation (Supplementary
Fig. 2) suggests that RCAN1.4 effects on receptor inter-
nalisation may be specific to VEGFR-2 in endothelial cells.
Analysis of the amino acid sequence of RCAN1.4 reveals
no classical SH2 or SH3 domains required for association
with RTKs, suggesting that RCAN1.4 may interact with
VEGFR-2 by a novel mechanism, possibly directly with
the VEGFR-2 or via ancillary proteins specifically required
for VEGFR-2 internalisation, such as neuropilin 1 (Nrp-1)
[45], synectin [46] and the recently described ephrin–B2
[47].
bFig. 6 RCAN1.4 stimulated cell migration requires VEGFR-2. a
HDMECs were plated on gelatin-coated plates and transfected with
either non-silencing siRNA (N.S. siRNA) or KDR siRNA prior to
incubation with adenovirus (Ad-Control) or adenovirus encoding
RCAN1.4 (Ad-RCAN1.4). Cells were lysed and immunoblotted with
antibodies to VEGFR-2, GAPDH and RCAN1. b Cells were
incubated with siRNA and adenovirus as above before a horizontal
wound was introduced to the well. Cells were fixed in 2% PFA. c
Results are plotted as cell migration, % of basal untreated response
(mean ± S.D., n = 3). ***P\ 0.001 (unpaired student’s t test)
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Fig. 7 RCAN1 and VEGFR-2
interaction at the leading edge
of migrating cells. a HDMECs
were plated on gelatin-coated
glass coverslips. A horizontal
wound was introduced on the
glass coverslip. Cells were
stimulated or not with VEGF
(50 ng/ml) for 1, 2, 5, 10 and
60 min. Cells were fixed in 2%
PFA, permeabilised and stained
for interaction between RCAN1
and VEGFR-2 using proximity
ligation reaction (PLA) with
antibodies to RCAN1 and
VEGFR-2. Scale bar represents
20 lm. b Quantification of
RCAN1/VEGFR-2 proximity
ligations. Cells were analysed at
the leading edge and also in the
main body with the number of
proximity ligations counted for
100 cells (mean ± s.e.m., n = 3
independent experiments).
**P\ 0.01, ***P\ 0.001
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It is also possible that RCAN1.4 can influence VEGFR-
2 phosphorylation, as RCAN1 depletion resulted in
decreased VEGFR-2 degradation and increased transient
phosphorylation on Y1175 (Fig. 1a). However, overex-
pression of RCAN1.4 did not appear to affect phosphory-
lation of VEGFR-2 under basal conditions but did appear
to transiently enhance VEGF-stimulated phosphorylation
of VEGFR-2 (Fig. 8a). Previous data have shown that
VEGFR-2 internalisation is required for phosphorylation of
Y1175 in VEGFR-2 in mouse endothelial cells [47].
Dephosphorylation of VEGFR-2 is regulated by a number
of recently identified phosphatases such as VE-PTP [11],
which causes delayed VEGFR-2 internalisation [48].
However, other data have shown that VEGFR-2 internali-
sation is not required for VEGF-mediated phosphorylation
in HUVECs [49]. Our data suggest that whilst RCAN1.4
levels can regulate VEGFR-2 internalisation and proteol-
ysis, effects on receptor phosphorylation are not as marked.
Studies on guided cell migration in Drosophila have
revealed the physiological role of RTK endocytosis is to
ensure localised intracellular response to guidance cues by
stimulating spatial restriction of signalling allowing
organised cell migration [50]. Recent data have shown that
VEGFR-2 endocytosis regulates endothelial sprout
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Fig. 8 RCAN1.4 binds to VEGFR-2. a HDMECs were plated on
gelatin-coated dishes and incubated with adenovirus (Ad-Control) or
adenovirus encoding RCAN1.1 (Ad-RCAN1.1) or RCAN1.4 (Ad-
RCAN1.4) isoforms. Cells were stimulated with VEGF (50 ng/ml) for
0, 2, 10 and 30 min. Cells were lysed and immunoprecipitation (IP)
was performed using antibodies to RCAN1 or control rabbit IgG.
Proteins were separated by SDS-PAGE and immunoblotted with
antibodies to phospho-VEGFR-2 (Y1175), VEGFR2, calcineurin-A,
GAPDH and RCAN1. Total cell lysate (TCL) was also analysed by
Western blotting. b Quantification of levels of VEGFR-2 and
phospho-VEGFR-2 in TCL. Levels are calculated relative to % of
basal Ad-Control (mean ± s.e.m. n = 3 independent experiments).
**P\ 0.01, ***P\ 0.001 (unpaired student’s t test)
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formation [51]. Our finding that RCAN1.4 regulates cell
polarity and cytoskeletal reorganisation at the leading edge
suggests that RCAN1.4 facilitates the coupling of VEGFR-
2 internalisation to generation of cell polarity at the leading
edge of a scratch wound and in tip cells in an angiogenic
sprout. In zebrafish, there are two orthologues of RCAN1,
RCAN1a and RCAN1b, but only the former encodes
orthologues of the alternatively spliced 1.1 and 1.4 iso-
forms (Ensemble genome browser). In this study, transla-
tion of RCAN1a-4 was specifically blocked giving rise to
defective vessel development, indicating that the function
of this splice variant is conserved across species.
The role of RCAN1 in vivo has been studied in
RCAN1-/- mice where gene ablation of RCAN1.1 and
RCAN1.4 resulted in mice with no anatomical differences
indicating that RCAN1 is not essential for development
[19]. However, the vasculature was not studied in detail
and it is possible that these mice may have more subtle
changes in their vasculature. It is also possible that other
members of the RCAN gene family compensate for the loss
of RCAN1 [52]. Interestingly, a role for RCAN1 in neurite
outgrowth and guidance has been recently identified [53].
Neurons from RCAN1-/- mice fail to orient towards brain-
derived neurotrophic factor (BDNF), whereas transgenic
RCAN1 neurons exhibit enhanced outgrowth. This data
suggest that TrkB, the receptor for BDNF, and VEGFR-2
may share a common requirement for RCAN1 proteins to
regulate neuronal cell and endothelial cell guidance,
respectively.
Our data describe a novel role for RCAN1.4 in regu-
lating VEGFR-2 internalisation and directed cell migration
(Fig. 10). Our current knowledge of RCAN1.4 is based on
its discovery as an endogenous competitive inhibitor of
calcineurin. This interaction with the catalytic domain of
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Fig. 9 RCAN1.4 regulates
endothelial cell sprouting and
vascular formation in zebrafish.
a In vitro sprouting
angiogenesis assay. HDMECs
were transfected with control
non-targeting siRNA (N.S.
siRNA) or RCAN1 siRNA prior
to incubation with cell tracker
dye green or orange. Cells were
mixed 1:1 and incubated with
carboxymethycellulose in ULA
96-well plates for 18 h prior to
embedding in collagen matrix.
Cells were stimulated with
VEGF (50 ng/ml) for 18 h and
fixed in 2% PFA prior to
fluorescence imaging. b
Quantification of endothelial tip
and stalk cell formation.
Sprouting tubes from VEGF
treated spheroids were
quantified (mean ± S.D.,
n = 3). ***P\ 0.001 (unpaired
Student’s t test). c Transgenic
fli1-GFP zebrafish embryos
were injected with mismatch or
RCAN1a-4 morpholino
oligonucleotides and imaged at
48 hpf. Scale bar represents
500 lm. d Analyses of total
vessel length and junction
number, n = 14 for mismatch,
n = 15 for RCAN morpholino.
Asterisk indicates P\ 0.01
(unpaired student’s t test)
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calcineurin is mediated via the exon 7 encoded c-terminus
of RCAN1.4 [54] and leads to downregulation of NFAT-
mediated inflammatory genes [22, 24]. Our data define a
novel role for RCAN1.4, in regulating VEGFR-2 inter-
nalisation and endothelial cell migration.
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